Combined MET and PD-L1 inhibition shows promise in MET-driven metastatic papillary renal cancer
by Vall d'Hebron Institute of OncologyCredit: Pixabay/CC0 Public DomainAdvanced papillary renal cancer (PRC) has a poor prognosis with few treatment options available. Approximately 30% of patient
Updated on: December 28,2023
10

Combined MET and PD-L1 inhibition shows promise in MET-driven metastatic papillary renal cancer
by Vall d'Hebron Institute of OncologyCredit: Pixabay/CC0 Public DomainAdvanced papillary renal cancer (PRC) has a poor prognosis with few treatment options available. Approximately 30% of patient
Updated on:December 28,2023
10
